Oncology Times:
doi: 10.1097/01.COT.0000292171.54139.9d
Department

PROTOCOL ALERT

Free Access
Article Outline
Collapse Box

Author Information

The following is a partial list of new clinical Trials recently added to the NCI's Physician Data Query (PDQ) database, accessible online at www.cancer.gov (Click on “Cancer Information”).

Back to Top | Article Outline

Gynecologic Cancer

GOG-0207

Randomized Study of Celecoxib in Patients With Cervical Intraepithelial Neoplasia 3

Phase of Trial: Phase II Status of Trial: Approved-not yet active Age Range: 17 and over Sponsor of Trial: NCI

STUDY LEAD ORGANIZATION

Gynecologic Oncology Group

Janet Sue Rader, MD, Protocol chair: 314-362-3181

Carolyn Muller, MD, Protocol co-chair: 214-648-3026; carolyn.muller@utsouthwestern.edu

Back to Top | Article Outline

Head & Neck Cancer

ICR-PARSPORT, EU-20304, ISRCTN48243537, MREC-03679

Randomized Study of Parotid-Sparing Intensity-Modulated Radiotherapy Versus Conventional Radiotherapy in Patients With Oropharyngeal or Hypopharyngeal Cancer at High Risk for Radiation-Induced Xerostomia

Phase of Trial: Phase III STUDY LEAD ORGANIZATION

Institute of Cancer Research - UK

Chris Nutting, Protocol chair: 44-020-7808-2586

MCSP-00-0107

Randomized Study of Benzydamine Hydrochloride for the Treatment of Radiation-Induced Oral Mucositis in Patients With Cancer of the Oral Cavity, Oropharynx, and/or Nasopharynx Undergoing Radiotherapy

Phase of Trial: Phase III Age Range: 18 and over Sponsor of Trial: Pharmaceutical/Industry STUDY LEAD ORGANIZATION

McNeil Consumer and Specialty Pharmaceuticals

Dennis Parenti, MD, Principal investigator: 215-273-8202

ID01-450, NCT00078416

Study of SCH 54031 in Surgically Resectable Squamous Cell Tumors of the Head and Neck

Phase of Trial: Phase II Age Range: 18 and over STUDY LEAD ORGANIZATION

University of Texas - MD Anderson Cancer Center

Katharine Gillaspy, RN: 713-745-6775; kgillaspy@mdanderson.org

BMS-200604, NCT00037089

A Paclitaxel, UFT, and Leucovorin in Patients with Metastatic Esophageal Cancer

Phase of Trial: Phase II Age Range: 18 to 79 STUDY LEAD ORGANIZATION

Marlene and Stewart Greenebaum Cancer Center, University of Maryland

Bristol-Myers Squibb Company

20000204, NCT00037518

A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer

Phase of Trial: Phase II Age Range: 18 and over Sponsor of Trial: Pharmaceutical/Industry STUDY LEAD ORGANIZATION

Amgen, Incorporated

Amgen Call Center: 866-572-6436 Ref# 00204; mit@amgen.com

SGN-00101-0005, NCT00038714

A Trial Study of SGN-00101 in Treating Pediatric Patients with Recurrent Respiratory Papillomatosis

Phase of Trial: Phase II Age Range: 2 to 18 Sponsor of Trial: Pharmaceutical/Industry STUDY LEAD ORGANIZATION

Stressgen Biotechnologies, Incorporated

Bryan A. Haas, PharmD, MS: 910-772-6657 x6657; bryan.haas@wilm.ppdi.com

H14214, NCT00078546

EBV-Specific CTLs Following CD45 Antibody to Patients with Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC)

Phase of Trial: Phase I STUDY LEAD ORGANIZATION

Baylor College of Medicine

Methodist Hospital

Texas Children's Hospital

Malcolm K. Brenner, MD, Study Chair: 832-824-4663; mbrenner@bcm.tmc.edu

UCCRC-12157B, NCI-1614

Intratumoral PV701 in Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the Head and Neck

Phase of Trial: Phase I Status of Trial: Approved-not yet active Age Range: 18 and over Sponsor of Trial: NCI STUDY LEAD ORGANIZATION

University of Chicago Cancer Research Center

David M. Gustin, MD, Protocol chair: 773-834-8634; 888-824-0200

Back to Top | Article Outline

Hematologic Malignancies

SKY0101-010, NCT00029523

DepoCyt Therapy in Patients with Neoplastic Meningitis from Lymphoma or a Solid Tumor

Phase of Trial: Phase IV Age Range: 18 and over Sponsor of Trial: Pharmaceutical/Industry STUDY LEAD ORGANIZATION

SkyePharma Inc., John E. Gait, MD, Jeff Miller, BSc; Ph: 858 625 2414 Ext.3357; jeffrey_miller@skyepharma.com

id01-087, NCT00038558

Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy

Phase of Trial: Phase III, Phase II Age Range: 16 and over STUDY LEAD ORGANIZATION

University of Texas - MD Anderson Cancer Center

P01899, NCT00044486

Prophylaxis Trial of Posaconazole vs. Standard Azole Therapy for Neutropenic Patients

Phase of Trial: Phase III Age Range: 13 to 65 Sponsor of Trial: Pharmaceutical/Industry STUDY LEAD ORGANIZATION

Schering-Plough Research Institute

CCBX001-049, NCT00078598

Rituximab versus Iodine I 131 Tositumomab Therapy for Patients with Non-Hodgkin's Lymphoma

Phase of Trial: Phase III Status of Trial: Approved-not yet active Age Range: 18 and over Sponsor of Trial: Pharmaceutical/Industry STUDY LEAD ORGANIZATION

Corixa

MSKCC-03139, CORAL-50-03B

Randomized Study of Rituximab, Ifosfamide, Carboplatin, and Etoposide Versus Rituximab, Dexamethasone, Cytarabine, and Cisplatin as Induction Therapy Followed By High-Dose Consolidation Chemotherapy and Autologous Stem Cell Transplantation With Versus Without Rituximab as Maintenance Therapy in Patients With Relapsed or Refractory CD20-Positive Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Phase of Trial: Phase III Age Range: 18 to 65 Sponsor of Trial: NCI STUDY LEAD ORGANIZATION

Memorial Sloan-Kettering Cancer Center

Craig Moskowitz, MD, Protocol chair: 212-639-2696;

moskowic@mskcc.org

CAM.NHL233, NCT00077961

Rituximab plus CAMPATH in Patients with Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL

Phase of Trial: Phase I/II Age Range: 18 and over Sponsor of Trial: Pharmaceutical/Industry STUDY LEAD ORGANIZATION

ILEX Oncology, Incorporated

Reyna Bishop, MS: 210-949-8456; rbishop@ilexonc.com

Kimberly Mitchell, RN: 210-949-8315; kmitchell@ilexonc.com

MSKCC-03126

Arsenic Trioxide and Imatinib Mesylate in Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Phase of Trial: Phase I/II Age Range: 18 and over Sponsor of Trial: NCI STUDY LEAD ORGANIZATION

Memorial Sloan-Kettering Cancer Center

Ellin Berman, MD, Principal investigator: 212-639-7762

BC-01-02, NCT00035022

Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas

Phase of Trial: Phase I/II Age Range: Any age Sponsor of Trial: Pharmaceutical/Industry STUDY LEAD ORGANIZATION

BioCryst Pharmaceuticals, Inc.

Tami S. Warren, RN: 866-600-2279; twarren@biocryst.com

ID01-010, NCT00038831

Allo Transplantation with Mylotarg, fludarabine and melphalan for AML, CML and MDS

Phase of Trial: Phase I/II Age Range: 55 to 75 STUDY LEAD ORGANIZATION

University of Texas - MD Anderson Cancer Center

DM99-412, NCT00038415

A Phase I/II Trial of Idiotypic Vaccination for Chronic Lymphocytic Leukemia Using a Genetic Approach

Phase of Trial: Phase I/II Age Range: Over 18 STUDY LEAD ORGANIZATION

University of Texas - MD Anderson Cancer Center

Michael J Keating, MB, BS: 713-745-2376; mkeating@mdanderson.org

William G Wierda, MD: 713-745-0428; wwierda@mdanderson.org

DM90-007, NCT00038376

Roferon and Accutane For Patients With T-Cell Malignancies

Phase of Trial: Phase II Age Range: 18 and over STUDY LEAD ORGANIZATION

University of Texas - MD Anderson Cancer Center

ID01-596, NCT00038571

Proteasome Inhibitor PS-341 For Patients With Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy

Phase of Trial: Phase II Age Range: Over 16 STUDY LEAD ORGANIZATION

University of Texas - MD Anderson Cancer Center

ID01-006, NCT00038610

Hyper-CVAD plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia

Phase of Trial: Phase II Age Range: 15 and over STUDY LEAD ORGANIZATION

University of Texas - MD Anderson Cancer Center

Deborah A. Thomas, MD: 713-745-4616; debthomas@mdanderson.org

ID01-541, NCT00038623

Yttrium-ibritumomab (Zevalan) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma

Phase of Trial: Phase II Age Range: 18 and over Sponsor of Trial: STUDY LEAD ORGANIZATION

University of Texas - MD Anderson Cancer Center

ID01-167, NCT00038675

Therapy of Hypereosinophilic Syndrome, Polycythemia Vera, Atypical CML or CMML with PDGF-R Fusion Genes, or Mastocytosis with Gleevec

Phase of Trial: Phase II STUDY LEAD ORGANIZATION

University of Texas - MD Anderson Cancer Center

0903B1-206-US, NCT00037583

Acute Myeloid Leukemia Study

Phase of Trial: Phase II Age Range: 18 and over Sponsor of Trial: Pharmaceutical/Industry STUDY LEAD ORGANIZATION

Wyeth Research

Back to Top | Article Outline

M. D. Anderson Again Named Top Cancer Hospital in US

For the third consecutive year and fourth time in five years, the University of Texas M. D. Anderson Cancer Center has been ranked the nation's top cancer hospital in U.S. News & World Report's “America's Best Hospitals” survey, published in the magazine's July 12 issue.

The top hospital overall, receiving that ranking for the 14th consecutive year, was Johns Hopkins, which was also given the #3 post for cancer treatment.

Rounding out the list for the publication's five top cancer hospitals were Memorial Sloan-Kettering Cancer Center (#2), Dana-Farber Cancer Institute (#4), and Mayo Clinic (#5).

© 2004 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share